APA (7th ed.) Citation

PK, J., KR, T., N, S., SJ, H., D, Z., R, S., . . . WG, H. (2025). The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): A rationale for the EASi-KIDNEY trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 40(6), 1175. https://doi.org/10.1093/ndt/gfae263

Chicago Style (17th ed.) Citation

PK, Judge, et al. "The Potential for Improving Cardio-renal Outcomes in Chronic Kidney Disease with the Aldosterone Synthase Inhibitor Vicadrostat (BI 690517): A Rationale for the EASi-KIDNEY Trial." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 40, no. 6 (2025): 1175. https://doi.org/10.1093/ndt/gfae263.

MLA (9th ed.) Citation

PK, Judge, et al. "The Potential for Improving Cardio-renal Outcomes in Chronic Kidney Disease with the Aldosterone Synthase Inhibitor Vicadrostat (BI 690517): A Rationale for the EASi-KIDNEY Trial." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 40, no. 6, 2025, p. 1175, https://doi.org/10.1093/ndt/gfae263.